Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19501163 | 1.00 | PIK3CD (0.44) | PIK3CDHRH3DPP8DPP7GSK3B | |
| SCHEMBL18427493 | 0.88 | PIK3CD (0.41) | PIK3CDACHEPOLB | |
| SCHEMBL12436 | 0.88 | PIK3CD (0.41) | PIK3CDACHEPOLB | |
| SCHEMBL27283973 | 0.88 | PIK3CD (0.41) | PIK3CDACHEPOLB | |
| SCHEMBL1687229 | 0.87 | PIK3CD (0.42) | PIK3CDHRH3CYP2D6SMN1; SMN2 | |
| SCHEMBL10150975 | 0.82 | PIK3CD (0.50) | PIK3CD | |
| SCHEMBL26286608 | 0.82 | DPP8 (0.35) | DPP8DPP7ACHE | |
| SCHEMBL21660212 | 0.82 | CARM1 (0.34) | PIK3CDDPP8DPP7 | |
| SCHEMBL22752520 | 0.82 | NCF1 (0.43) | PIK3CDHRH3GSK3BDYRK1AACHE | |
| SCHEMBL1515214 | 0.82 | PIK3CD (0.42) | PIK3CDHRH3GSK3BDYRK1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4227302-A1 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| WO-2017045751-A1 | COMPOUNDS AS ASIC INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | PIK3CD 1645/4885HRH3 3154/4885DPP8 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.